Systemic Markers of Inflammation in Neuroendocrine Tumors (NETs) and Outcomes With Everolimus: A Pooled Analysis From the Randomized, Phase 3 RADIANT-3, and RADIANT-4 Trials
Chan DL, Yao JC, Camaghi C, Herbst F, Ridolfi A, Strosberg J, Kulke MH, Pavel ME, Singh S (2019)
Publication Type: Conference contribution
Publication year: 2019
Journal
Book Volume: 48
Pages Range: 430-430
Journal Issue: 3
Authors with CRIS profile
Involved external institutions
Sunnybrook Health Sciences Centre
Canada (CA)
H. Lee Moffitt Cancer Center & Research Institute
United States (USA) (US)
Zentralkrankenhaus Bozen
Italy (IT)
Novartis Pharma S.A.S.
France (FR)
Royal North Shore Hospital (RNSH)
Australia (AU)
Dana–Farber Cancer Institute
United States (USA) (US)
University of Texas MD Anderson Cancer Center
United States (USA) (US)
Novartis AG
Switzerland (CH)
Canada (CA)
H. Lee Moffitt Cancer Center & Research Institute
United States (USA) (US)
Zentralkrankenhaus Bozen
Italy (IT)
Novartis Pharma S.A.S.
France (FR)
Royal North Shore Hospital (RNSH)
Australia (AU)
Dana–Farber Cancer Institute
United States (USA) (US)
University of Texas MD Anderson Cancer Center
United States (USA) (US)
Novartis AG
Switzerland (CH)
How to cite
APA:
Chan, D.L., Yao, J.C., Camaghi, C., Herbst, F., Ridolfi, A., Strosberg, J.,... Singh, S. (2019). Systemic Markers of Inflammation in Neuroendocrine Tumors (NETs) and Outcomes With Everolimus: A Pooled Analysis From the Randomized, Phase 3 RADIANT-3, and RADIANT-4 Trials. (pp. 430-430).
MLA:
Chan, David L., et al. "Systemic Markers of Inflammation in Neuroendocrine Tumors (NETs) and Outcomes With Everolimus: A Pooled Analysis From the Randomized, Phase 3 RADIANT-3, and RADIANT-4 Trials." 2019. 430-430.
BibTeX: Download